
EquitySector - HealthcareVery High Risk
Regular
NAV (08-Dec-25)
Returns (Since Inception)
Fund Size
₹88 Cr
Expense Ratio
2.45%
ISIN
INF397L01LG2
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-5.22%
+0.57% (Cat Avg.)
3 Years
+19.51%
+21.99% (Cat Avg.)
5 Years
+12.06%
+16.40% (Cat Avg.)
Since Inception
+17.04%
— (Cat Avg.)
| Equity | ₹86.24 Cr | 98.46% |
| Others | ₹1.35 Cr | 1.54% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹9.86 Cr | 11.47% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹4.93 Cr | 5.73% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.89 Cr | 5.68% |
| Cipla Ltd | Equity | ₹4.78 Cr | 5.56% |
| Neuland Laboratories Ltd | Equity | ₹4.17 Cr | 4.85% |
| Divi's Laboratories Ltd | Equity | ₹3.99 Cr | 4.64% |
| Fortis Healthcare Ltd | Equity | ₹3.87 Cr | 4.50% |
| Aurobindo Pharma Ltd | Equity | ₹3.84 Cr | 4.46% |
| Piramal Pharma Ltd | Equity | ₹3.71 Cr | 4.32% |
| Alkem Laboratories Ltd | Equity | ₹2.93 Cr | 3.41% |
| Abbott India Ltd | Equity | ₹2.91 Cr | 3.39% |
| Navin Fluorine International Ltd | Equity | ₹2.75 Cr | 3.20% |
| OneSource Specialty Pharma Ltd | Equity | ₹2.71 Cr | 3.15% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹2.67 Cr | 3.10% |
| Ipca Laboratories Ltd | Equity | ₹2.41 Cr | 2.81% |
| Concord Biotech Ltd | Equity | ₹2.37 Cr | 2.75% |
| Gland Pharma Ltd | Equity | ₹2.35 Cr | 2.73% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.33 Cr | 2.71% |
| Metropolis Healthcare Ltd | Equity | ₹2.2 Cr | 2.56% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹2.11 Cr | 2.46% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.95 Cr | 2.27% |
| Mankind Pharma Ltd | Equity | ₹1.93 Cr | 2.25% |
| Global Health Ltd | Equity | ₹1.86 Cr | 2.17% |
| Syngene International Ltd | Equity | ₹1.83 Cr | 2.13% |
| Treps | Cash - Repurchase Agreement | ₹1.53 Cr | 1.78% |
| Acutaas Chemicals Ltd | Equity | ₹1.53 Cr | 1.77% |
| Anthem Biosciences Ltd | Equity | ₹1.46 Cr | 1.69% |
| Vinati Organics Ltd | Equity | ₹1.38 Cr | 1.61% |
| Linde India Ltd | Equity | ₹0.93 Cr | 1.08% |
| Net Receivables / (Payables) | Cash - Collateral | ₹-0.21 Cr | 0.24% |
Large Cap Stocks
37.59%
Mid Cap Stocks
24.52%
Small Cap Stocks
34.64%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹78.08 Cr | 90.80% |
| Basic Materials | ₹6.59 Cr | 7.66% |
Standard Deviation
This fund
15.57%
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
0.82
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better

Since July 2023
ISIN INF397L01LG2 | Expense Ratio 2.45% | Exit Load 1.00% | Fund Size ₹88 Cr | Age 6 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹44,376 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (08-Dec-25)
Returns (Since Inception)
Fund Size
₹88 Cr
Expense Ratio
2.45%
ISIN
INF397L01LG2
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
28 Feb 2019
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
-5.22%
+0.57% (Cat Avg.)
3 Years
+19.51%
+21.99% (Cat Avg.)
5 Years
+12.06%
+16.40% (Cat Avg.)
Since Inception
+17.04%
— (Cat Avg.)
| Equity | ₹86.24 Cr | 98.46% |
| Others | ₹1.35 Cr | 1.54% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹9.86 Cr | 11.47% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹4.93 Cr | 5.73% |
| Torrent Pharmaceuticals Ltd | Equity | ₹4.89 Cr | 5.68% |
| Cipla Ltd | Equity | ₹4.78 Cr | 5.56% |
| Neuland Laboratories Ltd | Equity | ₹4.17 Cr | 4.85% |
| Divi's Laboratories Ltd | Equity | ₹3.99 Cr | 4.64% |
| Fortis Healthcare Ltd | Equity | ₹3.87 Cr | 4.50% |
| Aurobindo Pharma Ltd | Equity | ₹3.84 Cr | 4.46% |
| Piramal Pharma Ltd | Equity | ₹3.71 Cr | 4.32% |
| Alkem Laboratories Ltd | Equity | ₹2.93 Cr | 3.41% |
| Abbott India Ltd | Equity | ₹2.91 Cr | 3.39% |
| Navin Fluorine International Ltd | Equity | ₹2.75 Cr | 3.20% |
| OneSource Specialty Pharma Ltd | Equity | ₹2.71 Cr | 3.15% |
| Artemis Medicare Services Ltd Ordinary Shares | Equity | ₹2.67 Cr | 3.10% |
| Ipca Laboratories Ltd | Equity | ₹2.41 Cr | 2.81% |
| Concord Biotech Ltd | Equity | ₹2.37 Cr | 2.75% |
| Gland Pharma Ltd | Equity | ₹2.35 Cr | 2.73% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.33 Cr | 2.71% |
| Metropolis Healthcare Ltd | Equity | ₹2.2 Cr | 2.56% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹2.11 Cr | 2.46% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹1.95 Cr | 2.27% |
| Mankind Pharma Ltd | Equity | ₹1.93 Cr | 2.25% |
| Global Health Ltd | Equity | ₹1.86 Cr | 2.17% |
| Syngene International Ltd | Equity | ₹1.83 Cr | 2.13% |
| Treps | Cash - Repurchase Agreement | ₹1.53 Cr | 1.78% |
| Acutaas Chemicals Ltd | Equity | ₹1.53 Cr | 1.77% |
| Anthem Biosciences Ltd | Equity | ₹1.46 Cr | 1.69% |
| Vinati Organics Ltd | Equity | ₹1.38 Cr | 1.61% |
| Linde India Ltd | Equity | ₹0.93 Cr | 1.08% |
| Net Receivables / (Payables) | Cash - Collateral | ₹-0.21 Cr | 0.24% |
Large Cap Stocks
37.59%
Mid Cap Stocks
24.52%
Small Cap Stocks
34.64%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹78.08 Cr | 90.80% |
| Basic Materials | ₹6.59 Cr | 7.66% |
Standard Deviation
This fund
15.57%
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
0.82
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better

Since July 2023
ISIN INF397L01LG2 | Expense Ratio 2.45% | Exit Load 1.00% | Fund Size ₹88 Cr | Age 6 years 9 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹44,376 Cr
Address
4th Floor, Industrial Assurance Building, Mumbai, 400 020
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments